• Paul Kennedy has been named chairman/president/CEO of Ivax Diagnostics (Miami). Kennedy has more than 30 years of senior executive experience with Novo Nordisk France, Abbott France and Boots Co. Ltd., a UK-based healthcare retailer. Ivax also said that Patrice Debregeas has been appointed vice chairman and that Laurent Le Portz has been appointed to the board of directors and its audit and compensation committees. Patrice Debregeas is currently president of Debregeas & Associes Pharma, a Paris company specializing in drug development, while Le Portz is an investor with a strong experience in turnaround situations. Kevin Clark, COO of the company who also served as acting CEO since January, will remain with the company as COO as well as COO of ImmunoVision, the company's subsidiary located in Arkansas. On Sept. 2, a group controlled by Kennedy and Debregeas purchased all of the roughly 72% of the outstanding shares of the company owned by Teva Pharmaceutical Industries.

• MedCath (Charlotte, North Carolina) reported the resignation of Phil Mazzuca, executive vice president/COO since March 2006. Mazzuca will remain with MedCath for up to 90 days and then assume a post with a private healthcare company. Mazzuca's responsibilities will be assumed on an interim basis by O. Edwin French, president/CEO, and Derek Morkel, senior vice president, operations. The company said it has begun a search for a Hospital Division president to fill the post vacated by Mazzuca. MedCath owns an interest in and operates nine hospitals with a total of 676 licensed beds, located in Arizona, Arkansas, California, Louisiana, New Mexico, South Dakota and Texas and is in the process of developing its tenth hospital.